Organigram Holdings sets five-for-one share consolidation, cannabis stock adjusts capital base

Organigram Holdings is preparing a five-for-one share consolidation to support its Toronto listing. The Canadian cannabis producer is reshaping its capital structure while sector peers face tighter pricing and competition.

By Julia Schmitt, Sector & Peer Group desk. Reviewed prior to publication on 2026-06-26, 16:56.

Organigram Holdings Inc. (CA68620P1018) has confirmed that its previously approved share consolidation will proceed on a five-for-one basis, affecting its common shares listed on the Toronto Stock Exchange. The cannabis company disclosed the capital structure change in a detailed notice to investors, referencing shareholder approval at its most recent annual meeting and subsequent regulatory filings with the TSX and Canadian authorities.

What Organigram announced

Organigram Holdings said that the share consolidation will convert every five existing common shares into one new common share, with no fractional shares issued and any fractions rounded down, according to its corporate update and management information circular filed with Canadian regulators. The company's investor relations page describes the consolidation details including the effective date and record time that will be used by the Toronto Stock Exchange and other settlement systems.

The company explained that the consolidation is intended to reduce the number of issued and outstanding shares and may support an improved share price level, a frequent aim among cannabis producers facing investor fatigue and tighter capital markets, with similar moves seen previously at sector peer Aurora Cannabis on the Toronto Stock Exchange. Organigram also noted that the consolidation will not alter its authorized share capital, voting rights per share, or proportional ownership of existing shareholders aside from the mechanical reduction in share count.

Sector context on a Friday

Organigram operates in a Canadian cannabis sector that has undergone marked consolidation and cost-cutting, with companies such as Canopy Growth and Tilray Brands adjusting production footprints and capital structures in response to falling retail prices and intense competition. A recent Reuters overview of Canadian cannabis pricing pressures highlighted how producers are focusing on higher-margin product formats, brand differentiation, and disciplined inventory management.

Analyst commentary around Organigram and its peers remains cautious, with several brokers pointing to limited near-term earnings visibility for mid-cap cannabis names on the Toronto Stock Exchange and Nasdaq. Consensus data compiled by MarketScreener for Organigram Holdings show a mix of ratings, with price targets often tied to execution on premium product lines and any progress on regulatory developments in key markets such as Germany and the United States.

The product behind the stock

Organigram's revenue is built around branded cannabis products, including dried flower and pre-rolls, with the SHRED line of value-focused dried flower blends acting as a key portfolio pillar in Canadian retail channels. The company also offers ingestible products such as gummies and chocolate in selected provinces, with ongoing innovation in flavor and potency ranges.

Where the stock trades today

Organigram Holdings shares trade on the Toronto Stock Exchange under the ticker OGI, recently quoted at 2.10 Canadian dollars as of 2026-06-26, 15:30, according to TSX price data.

Organigram Holdings at a glance

• Company: Organigram Holdings Inc.
• ISIN: CA68620P1018
• WKN: A2QEG9
• Ticker: OGI
• Trading venue: Toronto Stock Exchange
• Price (as of 2026-06-26, 15:30): 2.10 CAD
• Market cap: 180 million CAD (as of 2026-06-26)
• Sector / industry: Consumer Staples - Cannabis Products
• Index membership: not a constituent of the S&P/TSX 60
• Next earnings date: not officially scheduled

This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.